GlaxoSmithKline PLC Director/PDMR Shareholding (5165D)
19 Febbraio 2020 - 5:24PM
UK Regulatory
TIDMGSK
RNS Number : 5165D
GlaxoSmithKline PLC
19 February 2020
GlaxoSmithKline plc (the ' Company ')
Vesting of Deferred Annual Bonus Plan Mandatory and Matching
Awards
This notification sets out the vesting details for the Chief
Executive Officer and other Persons Discharging Managerial
Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary
Shares and American Depositary Shares ('ADSs') made in 2017 under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan ('DABP') and
the associated Matching Awards, which were subject to relevant
business performance conditions. The three-year performance period
for the 2017 Matching Awards commenced on 1 January 2017 and ended
on 31 December 2019.
The performance measure vesting details for the DABP Matching
Awards are as follows:
Outcome and Vesting
Level
Portion Measure and Outcome % of maximum % of award
of the
Award
------------------------------------------- ------------- -----------
Adjusted Free Cash Flow - For the
three-year period, the Company achieved
Adjusted Free Cash Flow calculated
in accordance with the principles
for the measure of GBP13bn, which
is above the level of GBP12.95bn
required for maximum vesting.
Adjustments to the original target
and vesting schedule were communicated
1/3rd in the 2018 Annual Report. 100 33.333
------------------------------------------- ------------- -----------
Total Shareholder Return - For the
three years ending 31 December 2019,
the Company's Total Shareholder Return
ranked 8th, which is below the threshold
vesting level against a comparator
group of 10 global pharmaceutical
1/3rd companies including GSK. 0 0
------------------------------------------- ------------- -----------
R&D New Products - For the three-year
period, the Company achieved New
Product sales calculated in accordance
with the principles for the measure
of GBP7.254bn, which is above the
level of GBP5.099bn required for
maximum vesting. The threshold level
1/3rd was GBP4.172bn. 100 33.333
------------------------------------------- ------------- -----------
Total vesting for 2017 award 66.666%
Lapsed 33.334%
-------------------------------------------------------------------- -----------
The notifications that follow are for awards made to the Chief
Executive Officer and other PDMRs. They show the vesting of the
Deferred Annual Bonus Awards including dividends accrued, and the
proportion vesting in respect of the associated Matching Awards
i.e. conditional awards that vested according to performance,
including dividends accrued. The balance of the Matching Award made
to each PDMR has lapsed.
The vesting date for awards over Ordinary Shares was 17 February
2020. The vesting date for awards over ADSs was 18 February 2020.
The closing prices of Ordinary Shares and of ADSs of
GlaxoSmithKline plc on their respective vesting dates were
GBP16.616 and $43.55.
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Ms E Walmsley
=== ================================ ====================================================
b) Position/status Chief Executive Officer
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2017 under the Company's
2009 Deferred Annual Bonus Plan - Deferred
Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 37,221 (Deferred)
=== ================================ ================ ==============================
GBP0.00 24,815 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 62,036
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr R Connor
=== ================================ ====================================================
b) Position/status President, Global Vaccines
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2017 under the Company's
2009 Deferred Annual Bonus Plan - Deferred
Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 19,375 (Deferred)
=== ================================ ================ ==============================
GBP0.00 12,917 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 32,292
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr N Hirons
=== ================================ ====================================================
b) Position/status SVP, Global Ethics and Compliance
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2017 under the Company's
2009 Deferred Annual Bonus Plan - Deferred
Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00 12,243 (Deferred)
=== ================================ ================ ==============================
GBP0.00 8,163 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 20,406
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =====================================================================================
a) Name Mr B McNamara
==== ================================== =================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =====================================================================================
a) Name GlaxoSmithKline plc
==== ================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =====================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ================================== =================================================
b) Nature of the The number of ADSs released on awards granted
transaction in 2017 under the Company's 2009 Deferred
Annual Bonus Plan - Deferred Bonus and
Matching Awards.
==== ================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ================================== ================ =============================
$0.00 7,116 (Deferred)
==== ================================== ================ =============================
$0.00 4,745 (Matching)
================ =============================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price 11,861
$0.00
======================================= =================================================
e) Date of the transaction 2020-02-18
==== ================================== =================================================
f) Place of the N/A
transaction
==== ================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================================
a) Name Mr D Redfern
=== ================================ ====================================================
b) Position/status Chief Strategy Officer
=== ================================ ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================ ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================================
a) Name GlaxoSmithKline plc
=== ================================ ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================ ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================ ====================================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2017 under the Company's
2009 Deferred Annual Bonus Plan - Deferred
Bonus and Matching Awards.
=== ================================ ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================ ================ ==============================
GBP0.00. 15,407 (Deferred)
=== ================================ ================ ==============================
GBP0.00 10,273 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 25,680
Price GBP0.00
=== ================================ ====================================================
e) Date of the transaction 2020-02-17
=== ================================ ====================================================
f) Place of the N/A
transaction
=== ================================ ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =======================================================================================
a) Name Mr P Thomson
=== ================================= ====================================================
b) Position/status President, Global Affairs
=== ================================= ====================================================
c) Initial notification/ Initial notification
amendment
=== ================================= ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================================
a) Name GlaxoSmithKline plc
=== ================================= ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ================================= ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
=== ================================= ====================================================
b) Nature of the The number of Ordinary Shares released
transaction on awards granted in 2017 under the Company's
2009 Deferred Annual Bonus Plan - Deferred
Bonus and Matching Awards.
=== ================================= ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ================================= ================ ==============================
GBP0.00 7,302 (Deferred)
=== ================================= ================ ==============================
GBP0.00 4,869 (Matching)
================ ==============================
d) Aggregated information N/A (single transaction)
===
Aggregated volume 12,171
Price GBP0.00
=== ================================= ====================================================
e) Date of the transaction 2020-02-17
=== ================================= ====================================================
f) Place of the N/A
transaction
=== ================================= ====================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQKLFFBLLLBBB
(END) Dow Jones Newswires
February 19, 2020 11:24 ET (16:24 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
